Cargando…

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab

Introduction: Denosumab, an anti-resorptive medication approved for treatment of osteoporosis, increases bone mineral density and reduces fracture risk. Discontinuation of treatment is associated with bone turnover rebound and reduced bone mineral density. We report a case of a woman without prior h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caseja, Ahl Jeffrey, Abdullah, Najwa, Nakhle, Samer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090346/ http://dx.doi.org/10.1210/jendso/bvab048.443

Ejemplares similares

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

MON-356 Atypical Femur Fracture with Denosumab
por: Mirza, Faryal S, et al.
Publicado: (2020)

SAT-509 Denosumab Use in Tertiary Hiperparathyroidism with Fracture
por: Coy, Andres, et al.
Publicado: (2019)

Prolonged Hypocalcemia After a Single Dose of Denosumab in Chronic Kidney Disease
por: Puar, Akshan, et al.
Publicado: (2021)

FRI684 So Strong Yet So Fragile: Bilateral Periprosthetic Fractures On Denosumab
por: Syeda, Asma, et al.
Publicado: (2023)

RF30 | PSAT172 Effects of 12 Months of Alendronate Therapy Subsequent to 12 Months of Denosumab Administration in Women With Anorexia Nervosa
por: Haines, Melanie, et al.
Publicado: (2022)

SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)

ODP085 Denosumab Induced Severe Hypophosphatemia
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022)

PSAT190 Denosumab use for life-threatening hypercalcemia of malignancy in a toddler. A weight base dose
por: Castano, Gabriel, et al.
Publicado: (2022)

Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study
por: Khan, Aliya, et al.
Publicado: (2021)

Single Dose of Denosumab Effective for Management of Bisphosphonate-Refractory Hypercalcemia of Malignancy Related to Non-Small Cell Lung Cancer
por: Dinh, Kathryn, et al.
Publicado: (2021)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

OR30-2 Efficacy and Safety of Percutaneous Ethanol Ablation of Parathyroid Adenoma
por: Nakhle, Samer, et al.
Publicado: (2019)

Parathyromatosis Recurrent Hyperparathyroidism and Refractory Hypercalcemia Successfully Managed With Addition of Denosumab: A Case Report
por: Alhammad, Zahrah Abbas, et al.
Publicado: (2021)

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)

Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021)

THU426 Randomized Controlled Trial Comparing The Efficacy Of Teriparatide, Zoledronate And Denosumab In Postmenopausal Women With Type 2 Diabetes Mellitus At High Risk Of Fragility Fractures: 6-month Interim Analysis Of HR-pQCT Parameters
por: Pal, Rimesh, et al.
Publicado: (2023)

THU433 Spontaneous Vertebral Fractures In The Setting Of Prolonged CRRT
por: Akanbi, Folake, et al.
Publicado: (2023)

MON-517 Treatment of Gorham-Stout Disease with Combination Sirolimus and Denosumab
por: Hartley, Iris, et al.
Publicado: (2019)

SUN-513 Parathyromatosis: A Case of Stubborn Hypercalcemia Treated with Denosumab
por: Ventura, Kenilia, et al.
Publicado: (2019)

Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
por: Naher, Kamrun, et al.
Publicado: (2021)

SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

SUN-514 Severe Hypophosphatemia and Worsening Secondary Hyperparathyroidism Following Treatment with Denosumab
por: Adepoju, Yewande, et al.
Publicado: (2019)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

PSAT197 Treatment of Paget's Disease of the Skull With Denosumab: A Case Report
por: Torfah, Maisoon, et al.
Publicado: (2022)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

SAT258 Successful Treatment Of Adult T-cell Leukemia-lymphoma Induced Hypercalcemia With Denosumab
por: Yuksel, Simge, et al.
Publicado: (2023)

THU445 Complicated Course And Management After Denosumab Discontinuation: A Case Report
por: Arora, Ipsa, et al.
Publicado: (2023)

SUN-378 Unilateral Primary Aldosteronism as an Independent Risk Factor for Vertebral Fracture
por: Sakamoto, Ryuichi, et al.
Publicado: (2020)

RF18 | PMON103 Hypercalciuria in Young Adults With Primary Hyperparathyroidism Is Less Likely to Resolve After a Successful Parathyroidectomy Compare to Older Adults
por: Ayutyanont, Napatkamon, et al.
Publicado: (2022)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

ODP084 Denosumab as a therapuetic modality in management of primary hyperparathyroidism induced severe hypercalcemia
por: Mangaraj, Swayamsidha, et al.
Publicado: (2022)

THU447 Hungry Bone Syndrome Secondary To Denosumab Use In A Patient With Sleeve Gastrectomy
por: Kumar, Arathi Prabha, et al.
Publicado: (2023)

SAT-389 Clinical and Biochemical Characterization of Risk Factors for Vertebral Fractures in Patients with Hypoparathyroidism
por: Formenti, Anna Maria, et al.
Publicado: (2020)

SAT232 Patients With Chronic Hypoparathyroidism Have Higher Risk Of Vertebral Fracture And Lower Risk Of Femoral Fracture Compared To Controls
por: Bjornsdottir, Sigridur, et al.
Publicado: (2023)

OR01-5 Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study
por: Ibrahim, Quazi, et al.
Publicado: (2022)

MON-LB085 Blurred Vision and Hypocalcemia after Denosumab Injection in a Patient with Tertiary Hyperparathyroidism
por: Lim, Jayoung, et al.
Publicado: (2019)

SUN-512 Denosumab Improves Trabecular but Not Cortical Bone Osteoporosis in a Patient with Refractory Primary Hyperparathyroidism
por: Alhassan, Sharifa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_le889mdpadmlv3fuu96thbe9t6